(Finance) – Predictan innovative SME active in the healthcare sector which today entered the Euronext Growth Milan of the Italian Stock Exchange, closed the first half of 2024 with Sales Revenue equal to 1.26 million, down 46.3% compared to the figure at 30 June 2023 equal to €2.35 million.
EBITDA is equal to -0.16 million (0.27 million at 30 June 2023) while the EBITDA Margin is equal to -12.7% (11.3% at 30 June 2023).
THE’EBIT of the Company stands at approximately -0.29 million (approximately €0.05 million at 30 June 2023), while the net result for the period equal to € -0.31 million (vs. €0.02 million at 30 June 2023).
THE’Net Financial Debt Adjusted (IFN Adjusted) is equal to € -0.11 million, an increase compared to the value of € -1.75 million at 31 December 2023. The change is attributable to the absorption of cash and cash equivalents relating to the current management of the Company.
Angelo Aurelio Gigante, President and CEO of Predict: “We are determined to pursue our strategic objectives and, after an undoubtedly challenging first half of the year, we look to the future with optimism. In the second half of the year we will focus on the development of the most recently established SBUs, in particular Mistral, the flagship of our product portfolio and symbol of our capacity for innovation, while we expect profitable results from our traditional SBUs, whose business receives greater happened in the last months of the year. This cyclical pattern allows us to concentrate resources and skills on new growth areas. We are ready to seize new opportunities and consolidate our position in the market, thanks to the commitment and dedication of our team and the support and trust that investors will want to give us.”